<DOC>
	<DOCNO>NCT02352337</DOCNO>
	<brief_summary>The pancreas cancer 4th cause death . All stage confuse , survival 5 year note 5 % . At metastatic stage , pancreatic adenocarcinoma incurable disease survival median 2-4 month without chemotherapy . Up 2011 , gemcitabine reference treatment type cancer . But , FOLFIRINOX could permit improve significantly overall survival ( 6,8 month gemcitabine vs 11,1 month FOLFIRINOX ) progression free survival ( 3,3 month gemcitabine vs 6,4 month FOLFIRINOX ) patient 76 year . Main toxicity treatment hematological , gastrointestinal neuropathy apparition sensitive neuropathy , reversible , related oxaliplatin . These result population 76 year old . In study , median age patient inclusion 61 year old FOLFIRINOX still beneficial patient 65 year old . Given increase proportion patient 65 year old pancreatic cancer give increase life expect , important know effectiveness tolerance treatment patient old 65 year 76 year . FIRGEM original strategic sequential treatment witch alternate , every 2 month , 4 cycle FOLFIRI.3 2 cycle 3 injection gemcitabine . There cross resistance know 2 treatment witch limit toxicity preserve quality life patient . A Phase II trial test treatment regimen classical regimen gemecitabine , show overall survival 11 month FIRGEM regimen overall survival 8,2 month gemcitabine regimen . The rate progression 45 % near progression rate FOLFIRINOX . Tolerance close FOLFIRINOX regimen strategic n't induce limit neurotoxicities allow use oxaliplatin 2de line treatment . The trial propose evaluate effectiveness tolerance FOLFIRINOX regimen ( 8 cycle ) LV5FU2 maintenance ( could increase FOLFIRINOX tolerable without decrease efficiency ) , FIRGEM regimen FOLFIRINOX ( 12 cycle ) reference regimen .</brief_summary>
	<brief_title>First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 Maintenance Versus Firgem</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Metastatic disease At least one mesurable lesion accord RECIST V1.1 criteria No prior chemotherapy ( except least lestion irradition area ) Age &gt; 18 year . A favorable adviced onco geriatrician would mandatory inclusion patient older 75 old Performance statut ( WHO ) 01 Polynyclear ≥ 1500/mm3 Bilirubine ≤ 1,5 fois la LSN , creatinin &lt; 120μmol / L Signed informed consent form Another type pancreas tumor , endocrine tumor ou acinous cell Ampulloma Cerebral meningeal metastasis Gilbert disease Neuropathie &gt; = grade 1 Study treatment contraindication Uncontrolled diarrhoea inflamatory disease colon rectum , bowel obstruction bowel subobstruction resolve specific treatment Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease prevent patient receive study Cancer within 5 year inclusion , except int situ cancer neck uterus basal cell skin cancer Significant previous cardiac respiratory disease Patient include therapeutic study experimental treatment Pregnancy breast feed Patient depreved freedom gardianship Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
</DOC>